Comprehensive Stock Comparison
Compare Sanofi (SNY) vs AbbVie Inc. (ABBV) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | SNY | 5.5% revenue growth vs ABBV's 3.7% |
| Value | SNY | Lower P/E (11.5x vs 16.0x) |
| Quality / Margins | SNY | 16.7% net margin vs ABBV's 4.0% |
| Stability / Safety | SNY | Beta 0.35 vs ABBV's 0.42, lower leverage |
| Dividends | ABBV | 2.7% yield; 12-year raise streak; SNY pays no meaningful dividend |
| Momentum (1Y) | ABBV | +14.2% vs SNY's -6.6% |
| Efficiency (ROA) | SNY | 6.2% ROA vs ABBV's 1.8%, ROIC 5.5% vs 11.1% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Sanofi is a global pharmaceutical company that develops and markets prescription drugs, vaccines, and consumer healthcare products. It generates revenue primarily from its Pharmaceuticals segment — including specialty care and diabetes treatments — along with Vaccines and Consumer Healthcare divisions. The company's competitive advantage stems from its diversified portfolio, strong R&D pipeline, and established global commercial infrastructure.
AbbVie is a global biopharmaceutical company that develops and markets innovative medicines for serious health conditions. It generates revenue primarily from prescription drug sales — with immunology drugs like Skyrizi and Rinvoq now driving growth as Humira faces biosimilar competition — and also earns income from its aesthetics portfolio including Botox. The company's competitive advantage lies in its deep R&D pipeline, strong patent portfolio, and established commercial infrastructure for launching new blockbuster therapies.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
SNY leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). ABBV leads in 1 (Total Returns). 2 tied.
Financial Metrics (TTM)
ABBV and SNY operate at a comparable scale, with $59.6B and $46.7B in trailing revenue. SNY is the more profitable business, keeping 16.7% of every revenue dollar as net income compared to ABBV's 4.0%. On growth, SNY holds the edge at +59.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SNYSanofi | ABBVAbbVie Inc. |
|---|---|---|
| RevenueTrailing 12 months | $46.7B | $59.6B |
| EBITDAEarnings before interest/tax | $9.6B | $17.3B |
| Net IncomeAfter-tax profit | $7.8B | $2.4B |
| Free Cash FlowCash after capex | $8.3B | $20.6B |
| Gross MarginGross profit ÷ Revenue | +72.3% | +69.7% |
| Operating MarginEBIT ÷ Revenue | +13.6% | +15.2% |
| Net MarginNet income ÷ Revenue | +16.7% | +4.0% |
| FCF MarginFCF ÷ Revenue | +17.7% | +34.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +59.9% | +9.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -5.2% | -88.7% |
Valuation Metrics
At 20.3x trailing earnings, SNY trades at a 79% valuation discount to ABBV's 97.1x P/E. On an enterprise value basis, SNY's 11.9x EV/EBITDA is more attractive than ABBV's 27.0x.
| Metric | SNYSanofi | ABBVAbbVie Inc. |
|---|---|---|
| Market CapShares × price | $117.5B | $410.1B |
| Enterprise ValueMkt cap + debt − cash | $134.2B | $472.4B |
| Trailing P/EPrice ÷ TTM EPS | 20.32x | 97.08x |
| Forward P/EPrice ÷ next-FY EPS est. | 11.47x | 15.95x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 11.91x | 26.96x |
| Price / SalesMarket cap ÷ Revenue | 2.13x | 7.28x |
| Price / BookPrice ÷ Book value/share | 1.40x | 122.29x |
| Price / FCFMarket cap ÷ FCF | 11.21x | 23.00x |
Profitability & Efficiency
ABBV delivers a 62.2% return on equity — every $100 of shareholder capital generates $62 in annual profit, vs $11 for SNY. SNY carries lower financial leverage with a 0.30x debt-to-equity ratio, signaling a more conservative balance sheet compared to ABBV's 20.17x. On the Piotroski fundamental quality scale (0–9), SNY scores 7/9 vs ABBV's 6/9, reflecting strong financial health.
| Metric | SNYSanofi | ABBVAbbVie Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +10.9% | +62.2% |
| ROA (TTM)Return on assets | +6.2% | +1.8% |
| ROICReturn on invested capital | +5.5% | +11.1% |
| ROCEReturn on capital employed | +6.3% | +9.5% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.30x | 20.17x |
| Net DebtTotal debt minus cash | $14.1B | $62.3B |
| Cash & Equiv.Liquid assets | $7.7B | $5.5B |
| Total DebtShort + long-term debt | $21.8B | $67.8B |
| Interest CoverageEBIT ÷ Interest expense | 17.51x | 1.58x |
Total Returns (with DRIP)
A $10,000 investment in ABBV five years ago would be worth $24,166 today (with dividends reinvested), compared to $12,799 for SNY. Over the past 12 months, ABBV leads with a +14.2% total return vs SNY's -6.6%. The 3-year compound annual growth rate (CAGR) favors ABBV at 17.7% vs SNY's 5.4% — a key indicator of consistent wealth creation.
| Metric | SNYSanofi | ABBVAbbVie Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +0.9% | +1.9% |
| 1-Year ReturnPast 12 months | -6.6% | +14.2% |
| 3-Year ReturnCumulative with dividends | +17.0% | +63.1% |
| 5-Year ReturnCumulative with dividends | +28.0% | +141.7% |
| 10-Year ReturnCumulative with dividends | +70.2% | +413.0% |
| CAGR (3Y)Annualised 3-year return | +5.4% | +17.7% |
Risk & Volatility
SNY is the less volatile stock with a 0.35 beta — it tends to amplify market swings less than ABBV's 0.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ABBV currently trades 94.8% from its 52-week high vs SNY's 80.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SNYSanofi | ABBVAbbVie Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.35x | 0.42x |
| 52-Week HighHighest price in past year | $60.12 | $244.81 |
| 52-Week LowLowest price in past year | $44.62 | $164.39 |
| % of 52W HighCurrent price vs 52-week peak | +80.9% | +94.8% |
| RSI (14)Momentum oscillator 0–100 | 56.3 | 49.6 |
| Avg Volume (50D)Average daily shares traded | 3.2M | 5.7M |
Analyst Outlook
Wall Street rates SNY as "Buy" and ABBV as "Buy". Consensus price targets imply 17.2% upside for SNY (target: $57) vs 10.4% for ABBV (target: $256). ABBV is the only dividend payer here at 2.68% yield — a key consideration for income-focused portfolios.
| Metric | SNYSanofi | ABBVAbbVie Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $57.02 | $256.15 |
| # AnalystsCovering analysts | 27 | 39 |
| Dividend YieldAnnual dividend ÷ price | — | +2.7% |
| Dividend StreakConsecutive years of raises | 13 | 12 |
| Dividend / ShareAnnual DPS | — | $6.22 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.4% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Sanofi (SNY) | 100 | 96.98 | -3.0% |
| AbbVie Inc. (ABBV) | 100 | 254.41 | +154.4% |
AbbVie Inc. (ABBV) returned +142% over 5 years vs Sanofi (SNY)'s +28%. A $10,000 investment in ABBV 5 years ago would be worth $24,166 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Sanofi (SNY) | $34.7B | $46.7B | +34.6% |
| AbbVie Inc. (ABBV) | $25.6B | $56.3B | +119.7% |
Sanofi's revenue grew from $34.7B (2016) to $46.7B (2025) — a 3.4% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Sanofi (SNY) | 13.6% | 16.7% | +23.2% |
| AbbVie Inc. (ABBV) | 23.2% | 7.6% | -67.3% |
Sanofi's net margin went from 14% (2016) to 17% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Sanofi (SNY) | 12.8 | 23.9 | +86.7% |
| AbbVie Inc. (ABBV) | 29.3 | 74.4 | +153.9% |
Sanofi has traded in a 10x–44x P/E range over 9 years; current trailing P/E is ~20x. AbbVie Inc. has traded in a 17x–74x P/E range over 8 years; current trailing P/E is ~97x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Sanofi (SNY) | 1.83 | 2.03 | +10.9% |
| AbbVie Inc. (ABBV) | 3.63 | 2.39 | -34.2% |
Sanofi's EPS grew from $1.83 (2016) to $2.03 (2025) — a 1% CAGR.
Chart 6Free Cash Flow — 5 Years
Sanofi generated $9B FCF in 2025 (+5% vs 2021). AbbVie Inc. generated $18B FCF in 2024 (-19% vs 2021).
SNY vs ABBV: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is SNY or ABBV a better buy right now?
Sanofi (SNY) offers the better valuation at 20.3x trailing P/E (11.5x forward), making it the more compelling value choice. Analysts rate Sanofi (SNY) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SNY or ABBV?
On trailing P/E, Sanofi (SNY) is the cheapest at 20.3x versus AbbVie Inc. at 97.1x. On forward P/E, Sanofi is actually cheaper at 11.5x.
03Which is the better long-term investment — SNY or ABBV?
Over the past 5 years, AbbVie Inc. (ABBV) delivered a total return of +141.7%, compared to +28.0% for Sanofi (SNY). A $10,000 investment in ABBV five years ago would be worth approximately $24K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ABBV returned +413.0% versus SNY's +70.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SNY or ABBV?
By beta (market sensitivity over 5 years), Sanofi (SNY) is the lower-risk stock at 0.35β versus AbbVie Inc.'s 0.42β — meaning ABBV is approximately 21% more volatile than SNY relative to the S&P 500. On balance sheet safety, Sanofi (SNY) carries a lower debt/equity ratio of 30% versus 20% for AbbVie Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — SNY or ABBV?
Sanofi (SNY) is the more profitable company, earning 16.7% net margin versus 7.6% for AbbVie Inc. — meaning it keeps 16.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 16.2% versus 13.6% for SNY. At the gross margin level — before operating expenses — SNY leads at 72.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SNY or ABBV more undervalued right now?
On forward earnings alone, Sanofi (SNY) trades at 11.5x forward P/E versus 16.0x for AbbVie Inc. — 4.5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SNY: 17.2% to $57.02.
07Which pays a better dividend — SNY or ABBV?
In this comparison, ABBV (2.7% yield) pays a dividend. SNY does not pay a meaningful dividend and should not be held primarily for income.
08Is SNY or ABBV better for a retirement portfolio?
For long-horizon retirement investors, AbbVie Inc. (ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.42), 2.7% yield, +413.0% 10Y return). Both have compounded well over 10 years (ABBV: +413.0%, SNY: +70.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SNY and ABBV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. ABBV pays a dividend while SNY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.